281 related articles for article (PubMed ID: 15943823)
1. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
Kumar A; Woods KS; Bartolucci AA; Azziz R
Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
[TBL] [Abstract][Full Text] [Related]
2. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome.
Brennan K; Huang A; Azziz R
Fertil Steril; 2009 May; 91(5):1848-52. PubMed ID: 18439591
[TBL] [Abstract][Full Text] [Related]
4. The age-associated decline of androgens in reproductive age and menopausal Black and White women.
Spencer JB; Klein M; Kumar A; Azziz R
J Clin Endocrinol Metab; 2007 Dec; 92(12):4730-3. PubMed ID: 17895325
[TBL] [Abstract][Full Text] [Related]
5. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome.
Cho LW; Sathyapalan T; Kilpatrick ES; Keevil BG; Miller AG; Coady AM; Ahmed L; Atkin SL
BMC Endocr Disord; 2017 May; 17(1):26. PubMed ID: 28525998
[TBL] [Abstract][Full Text] [Related]
6. Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome.
Cinar N; Cetinozman F; Aksoy DY; Elcin G; Yildiz BO
J Eur Acad Dermatol Venereol; 2015 May; 29(5):875-80. PubMed ID: 25176476
[TBL] [Abstract][Full Text] [Related]
7. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women.
Elhassan YS; Idkowiak J; Smith K; Asia M; Gleeson H; Webster R; Arlt W; O'Reilly MW
J Clin Endocrinol Metab; 2018 Mar; 103(3):1214-1223. PubMed ID: 29342266
[TBL] [Abstract][Full Text] [Related]
8. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome.
Buyalos RP; Geffner ME; Azziz R; Judd HL
Hum Reprod; 1997 Jun; 12(6):1138-41. PubMed ID: 9221990
[TBL] [Abstract][Full Text] [Related]
9. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
10. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
Vermeulen A; Kaufman JM; Giagulli VA
J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
[TBL] [Abstract][Full Text] [Related]
11. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
12. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
Chen MJ; Han DS; Yang JH; Yang YS; Ho HN; Yang WS
Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
[TBL] [Abstract][Full Text] [Related]
13. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome.
Kauffman RP; Baker VM; DiMarino P; Castracane VD
Fertil Steril; 2006 Apr; 85(4):1010-6. PubMed ID: 16580388
[TBL] [Abstract][Full Text] [Related]
14. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
16. Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters.
Chapman IM; Wittert GA; Norman RJ
Clin Endocrinol (Oxf); 1997 Feb; 46(2):175-81. PubMed ID: 9135699
[TBL] [Abstract][Full Text] [Related]
17. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.
Sir-Petermann T; Maliqueo M; Angel B; Lara HE; Pérez-Bravo F; Recabarren SE
Hum Reprod; 2002 Oct; 17(10):2573-9. PubMed ID: 12351531
[TBL] [Abstract][Full Text] [Related]
18. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
19. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome.
Ducluzeau PH; Cousin P; Malvoisin E; Bornet H; Vidal H; Laville M; Pugeat M
J Clin Endocrinol Metab; 2003 Aug; 88(8):3626-31. PubMed ID: 12915646
[TBL] [Abstract][Full Text] [Related]
20. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
